gene therapy human severe combined immunodeficiency scid-x1 disease 
severe combined immunodeficiency-x1 scid-x1 x-linked inherited disorder characterized early block t natural killer nk lymphocyte differentiation block caused mutations gene encoding gamma c cytokine receptor subunit interleukin- receptors participates delivery growth survival differentiation signals early lymphoid progenitors preclinical studies gene therapy trial scid-x1 initiated based use complementary dna containing defective gamma c moloney retrovirus-derived vector ex vivo infection cd34+ cells month follow-up period gamma c transgene-expressing t nk cells detected two patients t b nk cell counts function including antigen-specific responses comparable age-matched controls thus gene therapy able provide full correction disease phenotype hence clinical benefit 
